JP2011501656A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011501656A5 JP2011501656A5 JP2010527128A JP2010527128A JP2011501656A5 JP 2011501656 A5 JP2011501656 A5 JP 2011501656A5 JP 2010527128 A JP2010527128 A JP 2010527128A JP 2010527128 A JP2010527128 A JP 2010527128A JP 2011501656 A5 JP2011501656 A5 JP 2011501656A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- sequence
- seq
- chain variable
- variable domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090001123 antibodies Proteins 0.000 claims 50
- 102000004965 antibodies Human genes 0.000 claims 50
- 239000003814 drug Substances 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 9
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 9
- 230000003042 antagnostic Effects 0.000 claims 8
- 239000005557 antagonist Substances 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 230000033115 angiogenesis Effects 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000035699 permeability Effects 0.000 claims 3
- 230000002792 vascular Effects 0.000 claims 3
- 206010003816 Autoimmune disease Diseases 0.000 claims 2
- 108010005144 Bevacizumab Proteins 0.000 claims 2
- 208000009745 Eye Disease Diseases 0.000 claims 2
- 230000035693 Fab Effects 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 238000004166 bioassay Methods 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000001519 tissues Anatomy 0.000 claims 2
- 102200130373 CA2 N62A Human genes 0.000 claims 1
- 102200029611 CKAP2L N62S Human genes 0.000 claims 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 claims 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102200066210 IL37 N54S Human genes 0.000 claims 1
- 102200124875 KRT17 N92S Human genes 0.000 claims 1
- 102200140067 PAWR L69I Human genes 0.000 claims 1
- 102200051231 PPA2 I48V Human genes 0.000 claims 1
- 102200011959 PSMB11 G49S Human genes 0.000 claims 1
- 102220410560 SDF2L1 T46L Human genes 0.000 claims 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims 1
- 102200024171 TPST1 N60A Human genes 0.000 claims 1
- 102200009351 TREX1 K66R Human genes 0.000 claims 1
- 102200125829 ZNF597 T30S Human genes 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 230000001419 dependent Effects 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 230000002055 immunohistochemical Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 102220008795 rs193922245 Human genes 0.000 claims 1
Claims (44)
- (1)アミノ酸配列KASQ−N/S−VGSDVA(配列番号:10)を含むLHVR1と(2)アミノ酸配列STSYRYS(配列番号:11)を含むLHVR2と(3)アミノ酸配列QQY−N/S−SYPFT(配列番号:12)を含むLHVR3とを含む軽鎖可変ドメイン配列並びに(1)アミノ酸配列GYTF−T/S−DYYLY(配列番号:13)を含むHHVR1と(2)アミノ酸配列GISPS−N/S−GGTTF−N/A−D−N/A−FE−N/G(配列番号:14)を含むHHVR2と(3)アミノ酸配列DAYGDWYFDV(配列番号:15)を含むHHVR3とを含む重鎖可変ドメイン配列を含む抗α5β1抗体。
- 配列番号:1、2、3、又は4の何れか一の配列又はその変異型を有する軽鎖可変ドメインと配列番号:5、6、7、8又は9の何れか一の配列又はその変異型を有する重鎖可変ドメインを含む抗α5β1抗体。
- 軽鎖可変ドメインが配列番号:2の配列を有し、重鎖可変ドメインが配列番号:6の配列を有する請求項2に記載の抗体。
- 軽鎖可変ドメインが配列番号:2の配列を有し、重鎖可変ドメインが配列番号:7の配列を有する請求項2に記載の抗体。
- 軽鎖可変ドメインが配列番号:3の配列を有し、重鎖可変ドメインが配列番号:8の配列を有する請求項2に記載の抗体。
- 軽鎖可変ドメインが配列番号:4の配列を有し、重鎖可変ドメインが配列番号:9の配列を有する請求項2に記載の抗体。
- 重鎖可変ドメインの可変領域が30、48、49、54、60、62、65、66、67及び69からなる群から選択される残基に一のアミノ酸置換を含む、請求項2に記載の抗体。
- 軽鎖可変ドメインが28、46及び92からなる群から選択される残基に一のアミノ酸置換を含む、請求項2に記載の抗体。
- アミノ酸置換がT30S、I48V、G49S、N54S、N60A、N62A、N62S、N65G、K66R、A67F及びL69Iからなる群から選択される、請求項7に記載の抗体。
- 軽鎖可変ドメインがN28S、T46L及びN92Sからなる群から選択されるアミノ酸置換を含む、請求項8に記載の抗体。
- 抗体がアルファVベータ3又はアルファVベータ5又はアルファVベータ1に結合しない、請求項1から10の何れか一項に記載の抗体。
- 抗体がヒトIgGのFc配列を含む請求項1から11の何れか一項に記載の抗体。
- ヒトIgGがhIgG1又はhIgG4である請求項12に記載の抗体。
- 抗体が抗体依存性細胞媒介性細胞障害(ADCC)エフェクター機能を欠いたFc配列を含む請求項12に記載の抗体。
- Fc配列がEU番号付けシステムに従うD265A置換を含む請求項14に記載の抗体。
- 抗体が、Fab、Fab’、F(ab)’2、単鎖Fv(scFv)、Fv断片;二重特異性抗体及び直線抗体である、請求項1から15の何れか一項に記載の抗体。
- 抗体が多価抗体である請求項1から15の何れか一項に記載の抗体。
- 抗体がヒト化又はキメラである、請求項1から17の何れか一項に記載の抗体。
- 抗体が単離されている、請求項1から18の何れか一項に記載の抗体。
- 治療薬をコンジュゲートした請求項1から19の何れか一項に記載の抗体。
- 治療薬が細胞毒性薬、放射性同位体及び化学治療薬からなる群から選択される、請求項20に記載の抗体。
- 標識をコンジュゲートした請求項1から21の何れか一項に記載の抗体。
- 標識が放射性同位体、蛍光色素及び酵素からなる群から選択される、請求項22に記載の抗体。
- 請求項1から23の何れか一項に記載の抗体をコードする単離された核酸分子。
- 請求項24の核酸分子をコードする発現ベクター。
- 請求項25の発現ベクターを含む細胞。
- 請求項26の細胞培養及び細胞培養からの抗体の回収を含む抗体の調製方法。
- 請求項1から23の何れか一項に記載の組成物及び製薬的に許容可能な担体。
- 請求項1から23の何れか一項の抗体をサンプルに接触させ、サンプル中のα5β1タンパク質を検出することにより、α5β1タンパク質に結合する抗α5β1抗体を検出する方法。
- 抗体が免疫組織化学アッセイ(IHC)又はELISAアッセイに使用される請求項29に記載の方法。
- 患者の血管新生及び/又は血管透過若しくは漏出を阻害するための請求項1から23の何れか一項に記載の抗体を含む医薬。
- 疾患が異常な血管新生又は血管透過若しくは漏出を有する、患者の疾患を治療するための請求項1から23の何れか一項に記載の抗体を含む医薬。
- VEGFアンタゴニストと併用する疾患に罹患した患者の血管新生及び/又は血管透過若しくは漏出を阻害するための請求項1から23の何れか一項に記載の抗α5β1抗体を含む医薬。
- VEGFアンタゴニストと併用する患者の癌の治療のための請求項1から23の何れか一項に記載の抗α5β1抗体を含む医薬。
- VEGFアンタゴニストと併用する患者の眼疾患の治療のための請求項1から23の何れか一項に記載の抗α5β1抗体を含む医薬。
- VEGFアンタゴニストと併用する患者の自己免疫疾患の治療のための請求項1から23の何れか一項に記載の抗α5β1抗体を含む医薬。
- 疾患に罹患していない患者の組織と比較して、患者の病変組織のα5β1量が上昇している請求項31から36の何れか一項に記載の医薬。
- 患者が抗腫瘍剤、化学治療薬、成長阻害剤及び細胞毒性薬からなる群から選択される治療薬を更に投与される、請求項31から37の何れか一に記載の医薬。
- VEGFアンタゴニストがベバシツマブによってヒトVEGFへの結合を競合的に阻害され得る、請求項33から38の何れか一に記載の医薬。
- VEGFアンタゴニストがベバシツマブである請求項39に記載の医薬。
- VEGFアンタゴニスト、請求項1から23の何れか一項に記載の抗α5β1抗体及び製薬的に許容可能な担体を含む組成物。
- (a)請求項1から23の何れか一項の抗体、及び(b)患者のアルファ5ベータ1を検出する指示書を含む患者のアルファ5ベータ1を検出するためのキット。
- (a)請求項1から23の何れか一項の抗α5β1抗体、及び(b)抗α5β1抗体の患者への投与のための指示書を含む患者の癌、眼疾患又は自己免疫疾患の治療のための製品。
- VEGFアンタゴニストを更に含む請求項43の製品。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97547107P | 2007-09-26 | 2007-09-26 | |
PCT/US2008/077622 WO2009042746A1 (en) | 2007-09-26 | 2008-09-25 | Novel antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011501656A JP2011501656A (ja) | 2011-01-13 |
JP2011501656A5 true JP2011501656A5 (ja) | 2011-11-10 |
Family
ID=40329277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010527128A Pending JP2011501656A (ja) | 2007-09-26 | 2008-09-25 | 新規抗体 |
Country Status (22)
Country | Link |
---|---|
US (3) | US7973138B2 (ja) |
EP (1) | EP2200700B1 (ja) |
JP (1) | JP2011501656A (ja) |
KR (1) | KR20100065162A (ja) |
CN (1) | CN101888878B (ja) |
AR (1) | AR066170A1 (ja) |
AU (1) | AU2008304452B2 (ja) |
BR (1) | BRPI0816049A2 (ja) |
CA (1) | CA2698609A1 (ja) |
CL (1) | CL2008002856A1 (ja) |
CO (1) | CO6260094A2 (ja) |
DK (1) | DK2200700T3 (ja) |
HR (1) | HRP20160308T1 (ja) |
HU (1) | HUE027911T2 (ja) |
MX (1) | MX2010003325A (ja) |
MY (1) | MY151191A (ja) |
NZ (1) | NZ584838A (ja) |
PE (1) | PE20091029A1 (ja) |
RU (1) | RU2490277C2 (ja) |
SI (1) | SI2200700T1 (ja) |
TW (1) | TWI547503B (ja) |
WO (1) | WO2009042746A1 (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR066170A1 (es) | 2007-09-26 | 2009-07-29 | Genentech Inc | Anti integrina alfa 5 beta 1 |
JP6051048B2 (ja) | 2009-03-25 | 2016-12-21 | ジェネンテック, インコーポレイテッド | 新規な抗α5β1抗体及びその使用 |
CA2665956A1 (en) * | 2009-05-07 | 2010-11-07 | Samir Patel | Combination treatment for ocular diseases |
CA2838400A1 (en) | 2009-05-08 | 2010-11-11 | Genentech, Inc. | Humanized anti-egfl7 antibodies and methods using same |
US8956600B2 (en) | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
US8852592B2 (en) | 2011-05-10 | 2014-10-07 | Biocare Medical, Llc | Systems and methods for anti-PAX8 antibodies |
US20130058926A1 (en) * | 2011-08-30 | 2013-03-07 | Shiseido Company, Ltd. | Method for alleviating and/or preventing skin reddening |
US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
US9494597B2 (en) * | 2012-04-02 | 2016-11-15 | Ab Biosciences, Inc. | Human control antibodies and uses therefor |
MX2019001355A (es) | 2012-05-10 | 2023-01-17 | Bioatla Llc | Anticuerpos monoclonales multiespecíficos. |
JP6324970B2 (ja) | 2012-09-27 | 2018-05-23 | バイオケア メディカル, エルエルシー | 抗ウロプラキンii抗体システムおよび方法 |
WO2014100220A2 (en) | 2012-12-18 | 2014-06-26 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
MX2015008534A (es) | 2012-12-26 | 2017-07-04 | Oncosynergy Inc | COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS. |
WO2014114298A1 (en) | 2013-01-23 | 2014-07-31 | Syddansk Universitet | Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors |
WO2014122144A1 (en) * | 2013-02-05 | 2014-08-14 | Engmab Ag | BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA |
EP2962113B1 (en) | 2013-02-28 | 2019-04-03 | Biocare Medical, LLC | Anti-p40 antibodies systems and methods |
US9816997B2 (en) | 2013-10-03 | 2017-11-14 | Biocare Medical, Llc | Anti-SOX10 antibody systems and methods |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
BR112018013407A2 (pt) | 2015-12-30 | 2018-12-18 | Kodiak Sciences Inc | anticorpos e conjugados dos mesmos |
CN108693004B (zh) * | 2018-05-24 | 2020-08-04 | 中国农业科学院农业质量标准与检测技术研究所 | 一种检测菜籽粕中是否掺杂抗生素滤渣的方法 |
CA3135836A1 (en) * | 2019-04-01 | 2020-10-08 | Lakepharma, Inc. | Btla-binding (cd272) antibodies for modulating immune response and treating disease |
AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
CN114688461A (zh) * | 2020-12-31 | 2022-07-01 | 青岛海尔施特劳斯水设备有限公司 | 一种漏水检测方法及系统 |
CN113133431A (zh) * | 2021-02-25 | 2021-07-20 | 中南大学 | 慢性高眼压合并长眼轴动物模型的建立方法、模型及应用 |
CN114073996B (zh) * | 2021-11-24 | 2023-04-14 | 中山大学 | 一种嵌套式微井阵列芯片及其制备方法 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5540933A (en) * | 1985-05-31 | 1996-07-30 | La Jolla Cancer Research Foundation | Isolation and use of fibronectin receptor |
EP0330506A3 (en) | 1988-02-26 | 1990-06-20 | Dana Farber Cancer Institute | Vla proteins |
US20020146410A1 (en) | 1992-05-22 | 2002-10-10 | Helmut Eckert | Monoclonal antibodies and their use |
US5981478A (en) | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
US5627263A (en) | 1993-11-24 | 1997-05-06 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
DK0719859T3 (da) * | 1994-12-20 | 2003-10-20 | Merck Patent Gmbh | Anti-alfa V-integrin monoklonalt antistof |
WO1999037683A1 (en) | 1998-01-23 | 1999-07-29 | Merck Patent Gmbh | MONOCLONAL ANTIBODY ANTI αv-INTEGRIN AND ITS USE TO INHIBIT αvβ6-INTEGRIN ATTACHMENT TO FIBRONECTIN |
US6852318B1 (en) * | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
EP1075277B2 (en) | 1998-05-08 | 2012-10-31 | The Regents of the University of California | Methods for detecting and inhibiting angiogenesis |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
GB9909392D0 (en) | 1999-04-24 | 1999-06-23 | Imp Cancer Res Tech | Treatment, imaging and diagnosis of disease |
CA2381699A1 (en) | 1999-08-11 | 2001-02-15 | Eos Biotechnology, Inc. | Novel methods of diagnosis of angiogenesis compostions and methods of screening for angiogenesis modulators |
US20020019330A1 (en) | 1999-08-11 | 2002-02-14 | Richard Murray | Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators |
US20030152926A1 (en) | 1999-08-11 | 2003-08-14 | Eos Biotechnology, Inc. | Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
US20040009494A1 (en) | 1999-08-11 | 2004-01-15 | Richard Murray | Novel methods of diagnosis of angiogenesis and other conditions, compositions, and the methods of screening for modulators |
US20020015970A1 (en) | 1999-08-11 | 2002-02-07 | Richard Murray | Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators |
US20040259152A1 (en) | 2000-02-22 | 2004-12-23 | Richard Murray | Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases |
WO2002079492A2 (en) | 2001-02-14 | 2002-10-10 | Protein Design Labs, Inc. | Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
CA2444691A1 (en) | 2001-04-18 | 2002-10-31 | Protein Design Labs, Inc. | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
WO2002098358A2 (en) | 2001-06-04 | 2002-12-12 | Eos Biotechnology, Inc. | Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer |
US7189507B2 (en) | 2001-06-18 | 2007-03-13 | Pdl Biopharma, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
AU2002347428A1 (en) | 2001-06-18 | 2003-01-02 | Eos Biotechnology Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
US20040076955A1 (en) | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
US20040033495A1 (en) | 2001-08-03 | 2004-02-19 | Eos Biotechnology, Inc. | Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
US20030124579A1 (en) | 2001-09-05 | 2003-07-03 | Eos Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
US20070042360A1 (en) | 2001-09-17 | 2007-02-22 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
WO2003025138A2 (en) | 2001-09-17 | 2003-03-27 | Protein Design Labs, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
US20030232350A1 (en) | 2001-11-13 | 2003-12-18 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
WO2004001384A2 (en) | 2002-06-25 | 2003-12-31 | The Regents Of The University Of California | Methods for inhibiting angiogenesis, cell migration, cell adhesion, and cell survival |
JP4667873B2 (ja) | 2002-07-16 | 2011-04-13 | アベンティス・ファーマシューティカルズ・インコーポレイテッド | α5β1およびその細胞生存経路を調節する能力 |
US7276589B2 (en) * | 2002-11-26 | 2007-10-02 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
AU2003298786A1 (en) | 2002-11-26 | 2004-06-18 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
US7285268B2 (en) * | 2002-11-26 | 2007-10-23 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
EP1575516B1 (en) * | 2002-11-26 | 2012-05-30 | Abbott Biotherapeutics Corp. | Chimeric and humanized antibodies to alpha5 beta1 integrin that modulate angiogenesis |
JP2007524605A (ja) | 2003-04-03 | 2007-08-30 | ピーディーエル バイオファーマ,インコーポレイティド | インテグリンα5β1のインヒビターおよび組織顆粒化の制御のためのそれらの使用 |
DK1755659T3 (da) * | 2004-03-24 | 2012-02-27 | Abbott Biotherapeutics Corp | Anvendelse af anti-alfa5beta1-antistoffer til inhibering af kræftcelleproliferation |
US20060008415A1 (en) | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
EP1819359B1 (en) | 2004-12-09 | 2015-03-18 | Janssen Biotech, Inc. | Anti-integrin immunoconjugates, methods of their production and their use |
JP2009516729A (ja) | 2005-11-23 | 2009-04-23 | アストラゼネカ アクチボラグ | L−フェニルアラニン誘導体 |
JP2009516730A (ja) | 2005-11-23 | 2009-04-23 | アストラゼネカ アクチボラグ | L−アラニン誘導体 |
US20090203663A1 (en) | 2006-02-09 | 2009-08-13 | Astrazeneca Ab | Chemical compounds |
ES2544957T3 (es) * | 2006-03-21 | 2015-09-07 | Genentech, Inc. | Terapia combinada que implica antagonistas alfa5beta1 |
BRPI0711796A2 (pt) | 2006-05-24 | 2011-12-06 | Bayer Schering Pharma Aktiendesellschaft | anticorpos de bloqueio de função de integrinas anti-alfa5beta1 humanos e humanizados com imunogenicidade reduzida |
AR066170A1 (es) | 2007-09-26 | 2009-07-29 | Genentech Inc | Anti integrina alfa 5 beta 1 |
CA2714071A1 (en) | 2008-02-05 | 2009-08-13 | Bristol-Myers Squibb Company | Alpha 5 - beta 1 antibodies and their uses |
-
2008
- 2008-09-25 AR ARP080104170A patent/AR066170A1/es unknown
- 2008-09-25 KR KR1020107006513A patent/KR20100065162A/ko active IP Right Grant
- 2008-09-25 AU AU2008304452A patent/AU2008304452B2/en not_active Ceased
- 2008-09-25 BR BRPI0816049A patent/BRPI0816049A2/pt not_active IP Right Cessation
- 2008-09-25 WO PCT/US2008/077622 patent/WO2009042746A1/en active Application Filing
- 2008-09-25 CN CN200880117702.0A patent/CN101888878B/zh not_active Expired - Fee Related
- 2008-09-25 RU RU2010116184/10A patent/RU2490277C2/ru not_active IP Right Cessation
- 2008-09-25 SI SI200831589T patent/SI2200700T1/sl unknown
- 2008-09-25 PE PE2008001669A patent/PE20091029A1/es not_active Application Discontinuation
- 2008-09-25 HU HUE08834260A patent/HUE027911T2/en unknown
- 2008-09-25 MX MX2010003325A patent/MX2010003325A/es active IP Right Grant
- 2008-09-25 NZ NZ584838A patent/NZ584838A/xx not_active IP Right Cessation
- 2008-09-25 US US12/237,640 patent/US7973138B2/en not_active Expired - Fee Related
- 2008-09-25 MY MYPI20101284 patent/MY151191A/en unknown
- 2008-09-25 TW TW097136935A patent/TWI547503B/zh not_active IP Right Cessation
- 2008-09-25 CL CL2008002856A patent/CL2008002856A1/es unknown
- 2008-09-25 JP JP2010527128A patent/JP2011501656A/ja active Pending
- 2008-09-25 EP EP08834260.5A patent/EP2200700B1/en active Active
- 2008-09-25 CA CA2698609A patent/CA2698609A1/en not_active Abandoned
- 2008-09-25 DK DK08834260.5T patent/DK2200700T3/en active
-
2010
- 2010-03-19 CO CO10033130A patent/CO6260094A2/es active IP Right Grant
-
2011
- 2011-05-20 US US13/112,833 patent/US9284376B2/en not_active Expired - Fee Related
- 2011-05-20 US US13/112,839 patent/US8840887B2/en not_active Expired - Fee Related
-
2016
- 2016-03-23 HR HRP20160308TT patent/HRP20160308T1/hr unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011501656A5 (ja) | ||
US9758586B2 (en) | Chimeric rabbit/human ROR1 antibodies | |
DK2493503T3 (en) | DOSAGE SCHEDULE FOR THE ADMINISTRATION OF A CD19xCD3 bispecific antibody | |
TWI640537B (zh) | PDGF受體β結合多肽 | |
KR20200016899A (ko) | 활성화가능 항-pdl1 항체, 및 이의 이용 방법 | |
AU2024202552A1 (en) | Neutralization of inhibitory pathways in lymphocytes | |
CN110799539A (zh) | 抗4-1bb抗体及其制备和使用方法 | |
TW201023855A (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan | |
JP2009536921A5 (ja) | ||
RU2013108054A (ru) | Антитела против а2 тенасцина с и способы их применения | |
WO2019137397A1 (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
EP3008093A1 (en) | Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer | |
JP2012521218A5 (ja) | ||
TW202110887A (zh) | 抗ror1/抗cd3雙特異性結合分子 | |
WO2018233624A1 (zh) | 抗Her2纳米抗体及其编码序列和用途 | |
IL297619A (en) | Use of a multimeric anti-dr5 binding compound in combination with cancer therapy for the treatment of cancer | |
CN109265547A (zh) | 一种抗cd47抗体及其应用 | |
CN112111008A (zh) | 抗cd73抗体及其应用 | |
CN109890843A (zh) | 一种abcg2单克隆抗体及其用途 | |
CN107148282A (zh) | 结合cxcr3的抗原结合蛋白 | |
JP2024054123A (ja) | 癌の治療のための配合剤 | |
WO2021082573A1 (zh) | 抗il-4r单域抗体及其应用 | |
WO2023169583A1 (zh) | 基于Pep42构建的双特异性细胞接合器分子的制备及其应用 | |
WO2022237647A1 (zh) | 针对dll3的结合分子及其应用 | |
US20230034186A1 (en) | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |